July 01, 2013
A New York federal judge on Monday denied Merck & Co. Inc.'s attempt to wipe out a $285,000 plaintiff verdict in a bellwether trial in multidistrict litigation claiming the bone drug Fosamax causes jaw deterioration, rejecting its argument that its warning was adequate.
February 05, 2013
Merck & Co. Inc. suffered a blow during the last bellwether trial in multidistrict litigation alleging bone drug Fosamax causes jaw deterioration, as a New York federal jury ruled Tuesday that the pharmaceutical giant failed to properly warn of the treatment's risks.